COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
  Global AdoptionAdoption
  Submit FeedbackFeedback (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Brunetti73%0.27 [0.08-0.89]death3/3311/33Scarsi85%0.15 [0.06-0.37]death122140Pinzón35%0.65 [0.34-1.21]death14/14523/156Sandhu42%0.58 [0.40-0.85]death16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]death16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Tau​2 = 0.19; I​2 = 76.0%Late treatment43%0.57 [0.38-0.85]1,228/8,3221,387/8,73743% improvementAll studies43%0.57 [0.38-0.85]1,228/8,3221,387/8,73743% improvement9 colchicine COVID-19 7/28/21Tau​2 = 0.19; I​2 = 76.0%; Z = 2.77 (p = 0.0028)Effect extraction pre-specifiedLower RiskIncreased Risk
Late Horby et al., medRxiv, doi:10.1101/2021.05.18.21257267 (Preprint) death, ↑1.0%, p=0.77 Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, mean 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none&qu..
Meta Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (Peer Reviewed) (meta analysis) meta-analysis Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Details   Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].
Late Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27) (Peer Reviewed) death, ↓43.9%, p=0.30 Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Details   RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.
Late Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Peer Reviewed) death, ↓5.5%, p=0.87 Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
Details   Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
Late Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954 (Peer Reviewed) death, ↓41.7%, p=0.0006 A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Details   Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
Late Pinzón et al., Research Square, doi:10.21203/ (Preprint) death, ↓34.5%, p=0.18 Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
Details   Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.
Late Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712 (Peer Reviewed) death, ↓84.9%, p<0.0001 Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Details   Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.
Late Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961 (Peer Reviewed) death, ↓72.7%, p=0.03 Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Details   PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.
Late Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12) (Peer Reviewed) death, ↓80.0%, p=0.49 Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Details   RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Late Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136 (Peer Reviewed) death, ↓77.3%, p=0.19 Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Details   RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.